Endo submits response to US FDA for Fortesta
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals has submitted its response to the US FDA for the complete response letter it received in October for the NDA of Fortesta (testosterone 2% gel), a treatment candidate for men with hypogonadism (scripnews.com, 20 October 2009).